Asia Pacific Hemostasis Diagnostics Market: By Product Type (Systems, Consumables, Point-of-Care Testing Devices), By Test Type (Fibrinogen Test, Activated Clotting Time, Platelet Function, Prothrombin Time, Heparin & Protamine Dose-Response Test For ACT, Activated Partial Thromboplastin Time, Anti-Factor Xa, Other Coagulation Tests), By Technology (Optical, Mechanical, Electrochemical, and Others), By End-User (Hospitals, Clinics, Diagnostic Laboratories, Others (POC)), and Country- Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023
Market Outline: Asia Pacific Hemostasis Diagnostics Market
Hemostasis diagnostics are the devices used to determine the hemostatic defects, which cause excessive bleeding. Hemostasis is defined as the stopping or slowing the blood flow from damaged blood vessel. During the hemostasis, blood changes from liquid state to the gelatinous state. Hemostasis maintained in the body by three mechanisms namely, blood coagulation, platelet plug formation, and vasoconstriction. Hemostasis diagnostics may help to predict the cause of bleeding during surgery by identifying the hemostatic defects in patients. Different types of tests such as prothrombin test, activated clotting time, platelet function, and other coagulation tests are carried to identify the hemostasis defects.
Market Dynamics: Asia Pacific Hemostasis Diagnostics Market
Increase in the prevalence of hemostasis related diseases in Asia Pacific countries majorly in India, China, Japan and South Korea, rise in R&D investment for novel tests and devices innovation, increase in healthcare expenditure, adoption of newer technologies, and high awareness about hemostasis diagnostics among healthcare professionals are boosting the hemostasis Asia Pacific diagnostics market. However, high cost of advanced hemostasis products, and stringent regulations for the test approvals are expected to hampering the growth of Asia Pacific hemostasis diagnostics market.
Market Scope: Asia Pacific Hemostasis Diagnostics Market
Hemostasis diagnostics market is segmented on the basis of product type, test type, technology, and end user
Based on the product type, market is segmented into the following:
- Systems
- Consumables
- Point-of-Care Testing Devices
Based on the test type, market is segmented into the following:
- Fibrinogen Test
- Activated Clotting Time
- Platelet Function
- Prothrombin Time
- Heparin & Protamine Dose-Response Test For ACT
- Activated Partial Thromboplastin Time
- Anti-Factor Xa
- Other Coagulation Tests
Based on the technology, market is segmented into the following:
- Optical
- Mechanical
- Electrochemical
- Others
Based on the end user, market is segmented into the following:
- Hospitals
- Clinics
- Diagnostic Centres
- Others (POC)
Regional Analysis: Asia Pacific Hemostasis Diagnostics Market
Geographically, Asia Pacific hemostasis diagnosis market is segmented into India, China, Japan, Australia, New Zealand, South Korea, and Rest of Asia Pacific. Japan hemostasis diagnostics market is growing due to increase in the prevalence of hemophilia, rise in R&D activities by market players, well-developed healthcare infrastructure. China hemostasis diagnostics market has a significant growth, which is attributed to rise in prevalence of cardiovascular diseases, launch of newer products in China, and expansion of the business by the market players in to the country. India hemostasis diagnostics market driven by increase in awareness about hemostasis diagnostics, adoption of newer technologies, and increase in prevalence of hemophilia (according to World Federation of Hemophilia Global Survey 2010, approximately 13,993 people are suffering from hemophilia) are bolster the market. Furthermore, increase in healthcare expenditure, rise in per capita income, and launching of newer tests into Asia Pacific region also boost the hemostasis diagnostics market.
Competition Assessment: Asia Pacific Hemostasis Diagnostics Market
Some of the players in the Asia Pacific hemostasis diagnostics market include:
- Hoffmann-La Roche Ltd. (Switzerland)
- Sysmex Corporation (Japan)
- Abbott Laboratories (U.S.)
- Alere Inc. (U.S.)
- Nihon Kohden Corporation (Japan)
- Siemens Healthineers (Germany)
- Grifols S.A (Spain)
- Beckman Coulter, Inc. (U.S.)
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and start-up’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
